EGA 2010 Psychedelic Symposium Dec 4-5 -Ticket Now available

[RonnySimulacrum]

http://img.photobucket.com/albums/v192/ronnysimulacrum/Basement-theatre---the-Spot---shop.jpg

 

EGA 2010 - Psychedelic Symposium

It is with great pleasure we announce our second Indoor EGA Symposium, held once again at the University of Melbourne. However this year we have extended the conference over both Saturday and Sunday and aim to provide an unprecedented professional and engaging program in the field of psychedelic studies. So get out your calendars and mark December 4-5 in your diary as the date for this year’s EGA.

 

If you wont to Know more about Entheogenesis Australis (EGA) follow this link:

http://www.entheo.net/EGA10_A4_v2LR.pdf

 

------------------------------------------------------------------------------------------------------------------------------------------------

 

Rick Doblin Headlining

It is with enormous delight that EGA will be bringing Rick Doblin to Australia to headline this year’s Symposium. Rick is the founder of MAPS (Multidisciplinary Association for Psychedelic Studies) a non-profit membership-based research and educational organization. Amongst other things, MAPS sponsors clinical studies intended to obtain US Food & Drug Administration [FDA] approval for the use of MDMA and LSD as prescription medicines. Without a doubt this is a massive opportunity for the Australian psychedelic community and we encourage you all to spread the news across your networks as Rick’s presence will draw interest from people across a wide variety of disciplines. We expect the 400 tickets to sell out very quickly this year, so get in early and make your plans for EGA well in advance.

 

Bio - Rick Doblin, Ph.D., - MAPS Executive Director

 

Rick founded MAPS in 1986. His dissertation (Public Policy, Harvard’s Kennedy School of Government) was on "The Regulation of the Medical Use of Psychedelics and Marijuana," and his master’s thesis (Harvard) focused on the attitudes and experiences of oncologists concerning the medical use of marijuana. His undergraduate thesis (New College of Florida) was a twenty-five year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He has also conducted a thirty-four year follow-up study to Tim Leary’s Concord Prison Experiment.

 

Rick studied with Stan Grof, M.D., and was in the first group to become certified as holotropic breathwork practitioners. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise "healthy" people, and to also become a legally licensed psychedelic therapist. He resides in Boston with his wife and three children.

 

The MAPS Web Page

http://www.maps.org

 

 

Other Keynote Speakers at EGA 2010

Dr Alex Wodak -

 

Bio: Dr Alex Wodak is a physician and since 1982 has been the Director of the Alcohol and Drug Service at St. Vincent’s Hospital, Darlinghurst, NSW. Major interests include prevention of alcohol and drug-related problems, harm reduction, treatment of drug users in prison and drug policy reform. Dr. Wodak is the President of the Australian Drug Law Reform Foundation and was President of the International Harm Reduction Association from 1996 to 2004. Dr. Wodak and colleagues established the first needle syringe programme and the first medically supervised injecting centre in Australia (when both were pre-legal). He is a member of a number of state and national committees and has often worked in developing countries to assist efforts to control HIV infection among injecting drug users. Dr. Wodak was awarded an AM in 2010.

 

Australian Drug Law Reform Foundation Web Page

http://adlrf.org.au

 

 

---------------------------------------------------------------------------------------------------------------------------------------------

 

Ticketing Info

Tickets for the 2010 EGA Psychedelic Symposium is very limited and on sale now.

There are only 350 tickets available to this conference, so be sure to get in early.

 

DATE AVAILABLE TICKETS PRICE

10/08/10 – 13/09/10 First Round $125

14/09/10 – 01/11/10 General admission $150 ($130 concession with ID)

02/11/10 – 29/11/10 Final boarding call $170 ( $155 concession with ID)

Daypass – Only 10 per day available @ $90, email us at entheogenesis<at symbol>gmail

 

To buy a ticket simply follow this link to the EGA Shop

http://www.entheo.net/egashop.php

 

---------------------------------------------------------------------------------------------------------------------------------------------

 

 

EGA 2010 will also be hosting new speakers from around Australia plus some of your old favorites

 

So stay pleases stay tuned everyone - and help spread the good EGA News in your networks and help keep EGA alive.

 

We hope to see you at EGA 2010.

 

Love and Light

 

RonnySimulacrum

& the EGA Team

http://www.entheo.net

::

[DarkSpark]

I really hope to be able to get down there for the EGA this year, might get one of my fellow southern stoners to put me up for a few days while i head on over to the Uni.

 

Props to everyone who pitches in to get the event working each year too !!!

[RonnySimulacrum]

Rick Doblin will be giving the following talks at this year’s EGA in Melbourne in early December.

 

Talk 1

TITLE: Psychedelics, Social Change, and Cultural Evolution

 

SYNOPSIS

We'll discuss the current renaissance in psychedelic research, the political dynamics at work, and a strategy for the reintegration of psychedelic experiences into Western culture.

There are now more psychedelic research studies taking place than at any time in the last 40 years. The symbolism of psychedelics as tools of political rebellion in the 1960s is subsiding and their scientific and therapeutic contributions are coming to the fore. Nevetheless, mainstreaming psychedelics back into Western culture is a delicate and slow-moving effort. In 396 AD, after about 2000 years of continuous celebration, the Eleusinian mystery ceremonies, considered by some experts to include a visionary/psychedelic component, were ended by the Christians. In 1962, almost 1600 years later, Harvard's Dr. Walter Pahnke conducted his Good Friday experiment in religiously-inclined subjects and demonstrated the potential of psilocybin to catalyze mystical experiences. By 1972, a cultural backlash ended virtually all psychedelic research for the next 20 years. In 1991, my follow-up study to the Good Friday study, conducted 25+ years after Pahnke's experiment, suggested a link between the subjects' mystical experiences and increased motivation for progressive (altruistic, compassionate) political involvement. Recent investigations at Johns Hopkins have confirmed the relationship between psilocybin and mystical experiences. The reintegration of psychedelics will likely require the demonstration of the pro-social benefits of the mystical experience. In addition, research studies demonstrating the therapeutic uses of psychedelic-assisted psychotherapy for PTSD, anxiety associated with end-of-life issues, and addiction will be required to more fully integrate psychedelic experiences into Western culture. Eventually, there will be networks of psychedelic therapy clinics in many towns. The mainstreaming of psychedelics will also require legal contexts for people seeking spiritual growth and rites of passage experiences, for freedom of religion in a personal sense. Post-prohibition harm reduction strategies such as psychedelic emergency services at cultural events, will reduce the likihood of future backlash.

 

Talk 2

TITLE: 'Developing Psychedelics into Prescription Medicines: MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder'

 

SYNOPSIS

After investing over $2 million and 24 years of dedicated effort, MAPS has completed two successful pilot studies of MDMA-assisted psychotherapy in patients with chronic, treatment-resistant PTSD (in the US and Switzerland), with additional pilot studies underway or in the approval process in Israel, Jordan and Canada. Yet we're still about 10 years and $10 million from the prescription approval of MDMA for PTSD. This lecture will address key points of MAPS’ international clinical development plan for MDMA-assisted psychotherapy, including protocol design, methodological challenges, development of our treatment manual and therapist training program and protocol, funding and political challenges. The studies of psychedelics in the treatment of anxiety and/or depression associated with end-of-life issues, of ibogaine and ayahuasca in the treatment of addiction and drug abuse, and of marijuana for a wide range of clinical conditions, will also be discussed. The talk will conclude with comments on how best to start psychedelic research in Australia.

 

Do Not Miss this

 

www.entheo.net